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Background~Aims: The role of cellular immunity 
in the clearance of hepatitis C virus after inter- 
feron therapy has not yet been elucidated. Here, 
we analyzed the T cell response to peptides from 
hepatitis C virus E1 protein in untreated and 
interferon-treated patients with chronic hepatitis 
C virus infection. 
Methods: We used thirty-six 15-mer synthetic pep- 
tides from hepatitis C virus E1 protein (genotype 
la) in a sensitive interleukin-2 production assay in 
two groups of controls (healthy seronegative indi- 
viduals and patients with liver diseases unrelated 
to hepatitis C virus), and three groups of patients 
with chronic hepatitis C: nine patients who cleared 
the virus after interferon treatment (group 1), nine 
patients who failed to respond to the therapy 
(group 2) and nine previously untreated patients 
(group 3). 
Results: None of the controls responded to any of 
the peptides tested, whereas 8/9 (88%) of patients 
from group 1 responded positively. In contrast, 
only 2/9 (22%) of patients from group 2 showed 
peptide recognition. In group 3, 5/9 patients (55 %) 
displayed positive response against E1 peptides. 
When E1 peptides from the sequence correspond- 
ing to genotype lb (the commonest in patients who 
were non-responders to interferon) were tested in 
nine additional interferon-resistant patients 
(group 2*) a positive response was detected in only 
three of them (33 %). 
Conclusions: T cell recognition of hepatitis C virus 
E1 peptides in patients with chronic hepatitis C 
who exhibit sustained response to interferon ther- 
apy is increased as compared with interferon-re- 
sistant cases, suggesting that T cell immunity to 
hepatitis C virus structural proteins may play a 
role in the clearance of this viral infection. 
Key words: Alpha-interferon; Cellular immune re- 
sponse; Hepatitis C virus; Interleukin-2; Synthetic 
peptides. 
EPATITIS C virus (HCV), the main causative agent 
of non-A, non-B hepatitis (1), has a strong ten- 
dency to develop chronic infection. Chronic hepatitis 
C (CHC) slowly evolves to cirrhosis and there is a 
risk of progression to hepatocellular carcinoma (2). 
Although interferon (IFN) is the only accepted treat- 
ment for CHC, only around 20% of treated cases ex- 
hibit a sustained response to this therapy (3). The 
mechanisms underlying the tendency to chronicity of 
Received 28 March; revised and accepted 21 November 1995 
Correspondence: Prof. J. Prieto, Department ofMedicine, 
School of Medicine, University of Navarra, 31008, Pam- 
plona, Spain. Telephone: 34-48-105600 Ext 6290. 
Fax: 34-48-105649. 
HCV infection and its resistance to IFN therapy are 
poorly understood. 
HCV infection induces the production of antibod- 
ies against structural and non-structural proteins of 
the virus, but it seems that humoral immunity occur- 
ring during the natural course of the disease provides 
little protection (4). Moreover, it has been shown that 
reinfection and new episodes of acute hepatitis occur 
in the presence of antibodies (5,6). Although cellular 
immunity is an essential mechanism in the defense 
against viral infections, the role of the T cell response 
in the control of HCV infection remains obscure (7- 
9). In order to investigate the role of cellular immu- 
nity in the clearance of HCV induced by IFN, we 
have selected three groups of patients: i) untreated 
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patients with chronic hepatitis C, ii) patients who 
cleared the virus after IFN therapy and iii) patients 
who did not respond to the treatment. In all these 
cases we have used a sensitive assay to determine the 
production of interleukin-2 (IL-2) by peripheral 
blood mononuclear cells in response to a panel of 36 
overlapping synthetic peptides from HCV E1 enve- 
lope glycoprotein. This envelope protein was chosen 
because it has been recently reported that immuniza- 
tion of chimpanzees with this protein (together with 
E2, the other envelope protein from HCV) has proved 
successful in protecting the animals against he chal- 
lenge with HCV (10). 
Our results show that while healthy individuals do 
not exhibit T cell responses against E1 peptides, posi- 
tive responses are found among patients with CHC. 
Of interest, most of the patients who clear HCV after 
IFN therapy manifest T cell reactivity against pep- 
tides from El, while the majority of IFN-resistant 
patients failed to respond to these antigens. Our data 
suggest hat HCV clearance after IFN treatment is
associated with the development of T cell immunity 
against viral structural proteins. 
Materials and Methods 
Patients and controls 
We studied 36 patients with chronic hepatitis C and 
two control groups consisting of six HCV seronega- 
tive healthy donors (three males and three females; 
age 26 to 33 years, mean age 28) and eight patients 
with liver diseases unrelated to HCV (three chronic 
hepatitis B, two primary biliary cirrhosis, two 
patients with alcohol-related liver disease and one 
non-A, non-B, non-C hepatitis; five males and three 
females; age 37 to 65, mean age 49). All chronic hep- 
atitis C patients were anti-HCV positive and showed 
liver biopsy changes indicative of chronic hepatitis 
(cirrhosis was present in four cases). Patients with 
chronic hepatitis C were subdivided into the follow- 
ing groups: Group 1. Nine patients (eight males and 
one female, age 23 to 50 years, mean age 31) who 
exhibited a sustained response to the treatment with 
alpha-IFN (3 MU daily for 2 months and 3 MU 3 
times a week for 8 to 10 months); all of them had nor- 
mal transaminase (ALT) levels and were HCV-RNA 
negative in serum by polymerase chain reaction 
(PCR) at least 1 year after treatment. Group 2. Nine 
IFN-resistant patients (six males and three females, 
age 34 to 66 years, mean age 54); these patients 
remained HCV-RNA positive in serum and showed 
high ALT values at the end of IFN treatment. Group 
3. Nine patients (five males and four females, age 26 
to 59 years, mean age 46) with CHC who did not 
receive previous antiviral treatment. All patients from 
these 3 groups were tested using peptides derived 
from the HCV sequence corresponding to genotype 
1 a. Since the most common genotype ncountered in 
patients manifesting IFN resistance is genotype lb, 
an additional group of nine patients, Group 2* (7 
males and 2 females, age 27 to 65 years, mean age 
42) who did not respond to IFN therapy were tested 
using peptides derived from the lb sequence. All the 
patients who received treatment were studied at the 
end of the therapy (4 to 24 months after stopping 
IFN). 
Peptide synthesis 
Peptides were synthesized by the solid-phase method 
of Merrifield (11) using the Fmoc alternative (12). 
Synthesis was carried out using a manual multiple 
solid-phase peptide synthesizer (13) and the ninhy- 
drin test of Kaiser was used to monitor every step 
(14). Couplings were repeated if necessary until a 
negative ninhydrin test was attained. At the end of the 
synthesis, peptides were cleaved, deprotected and 
washed six times with diethyl ether. Peptide purity 
was above 70% as assessed by HPLC, and peptides 
were used without further purification. 
IL-2 production assay 
Peripheral blood mononuclear cells (PBMC) were 
isolated from fresh heparinized blood by Ficoll- 
Hypaque centrifugation. Cells were resuspended in
RPMI 1640 medium supplemented with 10% heat- 
inactivated human pooled AB serum, 100 U/ml peni- 
cillin and 100 ~tg/ml streptomycin, plated at 2x105 
cells/well and cultured in triplicate in 96-well fiat- 
bottom plates with 10 ~tg/ml of BT563 anti-IL-2 
receptor mAb (Biotest Pharma, Germany) in the pres- 
ence or absence of synthetic peptides (25 ~tg/ml). 
Mitogen stimulation of cells was carried out by incu- 
bation with phytohaemagglutinin (PHA), 1/200 final 
dilution (Gibco). After 7 days of culture, supernatants 
were harvested and stored at -20°C IL-2 content was 
assessed by examining the ability of the supernatant 
to support he growth of an IL-2-dependent CTLL 
mouse cell line. 
CTLL cells were resuspended in RPMI 1640 sup- 
plemented with 10% fetal calf serum, 100 U/ml peni- 
cillin, 100 ~tg/ml streptomycin and 2-mercaptoetha- 
nol (5×10 -5 M), and were plated (8×103 cells/well) in 
a 96-well fiat-bottom plate with the supernatant to be 
assayed (25% v/v). Following 24 h of culture, cells 
TABLE 1 
Synthetic peptides from HCV E1 
Peptide Sequence 1 a Sequence 1 b 
number 
1 YQVRNSTGLYHVTND 
6 STGLYHVTNDCPNSS 
11 HVTNDCPNSSIVYEA 
16 CPNSSIVYEAHDAIL 
21 IVYEAHDAILHTPGC 
26 HDAILHTPGCVPCVR 
31 HTPGCVPCVREGNVS 
36 VPCVREGNVSRCWVA 
41 EGNVSRCWVAMTPTV 
46 RCWVAMTPTVATRDG 
51 MTPTVATRDGKLPAT 
56 ATRDGKLPATQLRRH 
61 KLPATQLRRHIDLLV 
66 QLRRHIDLLVGSATL 
71 IDLLVGSATLCSALY 
76 GSATLCSALYVGDLC 
81 CSALYVGDLCGSVFL 
86 VGDLCGSVFLIGQLF 
91 GSVFLIGQLFTFSPR 
96 IGQLFTFSPRRHWTT 
101 TFSPRRHWTTQGCNC 
106 RHWTTQGCNCSIYPG 
111 QGCNCSIYPGHITGH 
116 SIYPGHITGHRMAWD 
121 HITGHRMAWDMMMNW 
126 RMAWDMMMNWSPTAA 
131 MMMNWSPTAALVMAQ 
136 SPTAALVMAQLLRIP 
141 LVMAQLLRIPQAILD 
146 LLRIPQAILDMIAGA 
151 QAILDMIAGAHWGVL 
156 MIAGAHWGVLAGIAY 
161 HWGVLAGIAYFSMVG 
166 AGIAYFSMVGNWAKV 
171 FSMVGNWAKVLVVLL 
176 NWAKVLVVLLLFAGV 
YEVRNVSGLIHVTND 
VSGLIHVTNDCSNSS 
HVTNDCSNSSIVYEA 
CSNSSIVYETADMIM 
IVYETADMIMHTPGC 
ADMIMHTPGCVPCVR 
HTPGCVPCVREGNSS 
VPCVREGNSSRCWVA 
EGNSSRCWVALTPTL 
RCWVALTPTLAAKDA 
LTPTLAAKDASIPTA 
AAKDASIPTATIRRH 
SIPTATIRRHVDLLV 
TIRRHVDLLVGAAAF 
VDLLVGAAAFCSAMY 
GAAAFCSAMYVGDLC 
CSAMYVGDLCGSVFL 
VGDLCGSVFLVSQLF 
GSVFLVSQLFTFSPR 
VSQLFTFSPRRHQTV 
TFSPRRHQTVQDCNC 
RHQTVQDCNCSIYPG 
QDCNCSIYPGHVSGH 
SIYPGHVSGHRMAWD 
HVSGHRMAWDMMMNW 
RMAWDMMMNWSPTAA 
MMMNWSPTAALVVSQ 
SPTAALVVSQLLRIP 
LVVSQLLRIPQAVVD 
LLRIPQAVVDMVAGA 
QAVVDMVAGAHWGVL 
MVAGAHWGVLAGLAY 
HWGVLAGLAYYSMVG 
AGLAYYSMVGNWAKV 
YSMVGNWAKVLVVML 
NWAKVLVVMLLFAGV 
Peptide sequences correspond to HC-J1, described by Okamoto et al. 
(18), classified as genotype la and to a viral isolate classified as lb 
(David Parker, Wellcome Laboratories, personal communication). 
Peptides contain an extra Ala at the C-terminus (not shown) that was 
added for synthesis convenience. 
were pulsed with 1 t.tCi/well of [3H]thymidine for 18 
h and thymidine incorporation was determined. The 
results are expressed as stimulation index (SI), cpm 
incorporated in response to a peptide divided by the 
cpm incorporated in the absence of peptide. The 
response against a peptide was considered positive 
when SI >3. 
IL-2 production against HCV E1 peptides 
Determination of HCV-RNA 
This was performed using the polymerase chain reac- 
tion (PCR) as previously described (15). 
Identification of HCV genotypes 
Genotyping was carried out using a hybridization 
technique with specific probes for HCV genotypes 
la, lb, 2a, 2b and 3a, according to Simmonds et al. 
(16), and the amplified HCV core region by nested 
PCR. The same probes and primers described by Via- 
zov et al. (17) were used, with the following technical 
modifications: the primers for the second PCR were 
5" labelled with digoxigenine, and hybridization was 
detected using an anti-digoxigenine peroxidase- 
labelled antibody (Boehringer Mannhein). 
HLA-DR typing 
HLA-DR determination was done by using the 
Standard INNO-LIPA HLA DR kit (Innogenetics, 
Belgium). Assays were performed according to the 
manufacturer's instructions. 
Statistical analysis 
Differences between groups were analyzed by 
Fisher's exact test. Relative risk associated to some 
HLA-DR was estimated using the odds-ratio 
(obtained with SPSS for Windows). 
Results 
To analyze the reactivity of T cells against antigenic 
determinants from the HCV envelope protein E 1, we 
used 36 15-mer overlapping peptides (10 amino acids 
overlap) encompassing the entire sequence of this 
glycoprotein to stimulate PBMC from controls 
(healthy individuals and patients with non-HCV- 
related liver disease), from patients with chronic 
HCV infection and from patients who cleared the 
virus after IFN treatment. The peptide sequence, 
shown in Table 1, corresponds to HC-J1 (18), geno- 
type la. 
Each peptide from Table 1 was tested in PBMC 
from patients with HCV infection and controls by 
measuring IL-2 production as described in Methods. 
None of the peptides gave a positive response in any 
of the individuals belonging to the control groups 
(HCV seronegative healthy donors and patients with 
liver disease unrelated to HCV) (data not shown). 
The recognition of peptides by the different groups of 
patients with chronic hepatitis C was as follows: 
As shown in Fig. 1, 8/9 (88%) of patients from 
group 1 (those having cleared HCV following treat- 
ment with IFN) responded to peptides from El. The 
number of peptides recognized by each of the react- 
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Fig. 1. IL-2 production in different 
groups of HCV patients against HCV 
E1 synthetic peptides (sequence la). 
Peptide sequences correspond to 
those shown in Table 1. Group 1 to 3 
are as follows: (1) Patients having 
cleared HCV following IFN treat- 
ment. (2) Patients who at the end of 
IFN treatment still had high ALT lev- 
els. (3) Patients not having been sub- 
jected to IFN treatment. Data are 
represented as stimulation index, SI 
(cpm with peptide/cpm without pep- 
tide) as indicated. 
ing patients varied between 2 and 10 (mean 4.5). 
There was a great variability between the different 
individuals of this group with respect o the identity 
of the specific peptides which were recognized as 
well as to the values of the stimulation index (SI). 
Peptides inducing positive responses were distributed 
all along the E1 sequence. Of the 36 peptides tested 
21 (58%) elicited a positive response in at least one of 
the patients from this group. The most commonly 
recognized peptides were 171 and 176 which were 
both detected in three out of nine of the patients tud- 
ied. The mean SI for positively recognized peptides 
was 4.9, ranging from 3 to 8. 
Only 2/9 (22%) of the patients from group 2 (IFN 
resistant cases) exhibited a positive response to some 
of the peptides, a proportion which is significantly 
lower than in group 1 (p<0.01). The number of pep- 
tides recognized by patients from group 2 was also 
lower than in group 1 (p<0.01). Only 3 peptides elic- 
ited T cell response in patients from group 2: one of 
the subjects recognized 1 peptide and the other 
patient 2 peptides. The SI for these peptides was very 
low, just above the cut-off value of 3. 
Five out of nine (55%) of the patients from group 3 
(untreated patients with CHC) recognized peptides 
from El. The number of peptides eliciting a positive 
T cell response varied between 1 and 5 per patient 
(mean 3). Ten of the 36 peptides tested (27%) were 
recognized by at least one of the patients from this 
group. The mean SI for recognized peptides was 4.4. 
Fig. 1 shows the specific peptides eliciting positive 
responses in group 3: it can be seen that peptide 131 
was the most commonly recognized peptide (3 out of 
9 patients) in this group. Six of the patients from 
group 3 were then subjected to IFN therapy (patients 
#19, 21, 22, 23, 26, 27). Two of them (#21 and 22) 
tested negatively for all the peptides, while four (#19, 
23, 26, 27) showed a positive response to some E1 
peptides. Interestingly, the former two failed to 
respond to IFN, while patients #19, 26 and 27 exhib- 
ited a positive response to the therapy. 
We determined the genotype of HCV in untreated 
patients from the sera collected uring the year before 
the assay and in those patients who completed IFN 
therapy from the sera collected uring the year before 
treatment. As shown in Table 2, most patients who 
did not respond to IFN were infected with HCV gen- 
otype lb. In contrast, in the group of patients who 
cleared the virus following IFN treatment, the geno- 
types were more evenly distributed. Thus in group 1, 
from a total of nine patients, two, three, three and one 
were found to be infected with genotypes la, lb, 3 
4 
TABLE 2 
Genotyping of HCV in patients with CHC 
IL-2 production against HCV E1 peptides 
Group 1 Group 2 Group 3 Group 2* 
Patient a Genotype Patient a Genotype Patient a Genotype Patient a Genotype 
1 la 10 la 19 3 28 lb 
2 lb 11 la 20 lb 29 lb 
3 3 12 lb 21 lb 30 lb 
4 lb 13 lb 22 la 31 lb 
5 3 14 lb 23 lb 32 lb 
6 lb/3 15 lb 24 ND 33 3 
7 la 16 lb 25 lb 34 3 
8 lb 17 lb 26 la 35 lb 
9 3 18 3 27 lb 36 lb 
Genotype of HCV in untreated patients was done from the sera collected uring the last tear before the assay and in those patients who completed 
IFN therapy from the sera collected uring the last year before treatment, a Patient numbers correspond tothose from Fig. 1 and Fig. 2. * This 
group of patients i  equivalent to group 2, but it was tested against peptides from genotype 1 b. ND: Not determined. 
TABLE 3 
Production of IL-2 after mitogen stimulation (PHA) 
Group 1 Group 2 Group 3 Group 2* 
Patient IL-2 (SI) Patient IL-2 (SI) Patient IL-2 (SI) Patient IL-2 (SI) 
1 56 10 160 19 90 28 172 
2 70 11 57 20 167 29 116 
3 170 12 35 21 270 30 77 
4 162 13 132 22 164 31 91 
5 192 14 240 23 417 32 70 
6 129 15 83 24 103 33 131 
7 103 16 139 25 141 34 77 
8 220 17 225 26 48 35 171 
9 121 18 81 27 52 36 123 
Mean (SD) 135 (51) 128 (67) 161 (111) 114 (36) 
Results are expressed as stimulation i dex, SI (cpm with PHA stimulation/cpm without PHA stimulation). 
and lb+3, respectively. Untreated patients (group 3) 
were infected with genotype lb (five patients), la 
(two patients) and 3 (one patient). 
Since non-responders to IFN treatment were 
mainly infected with genotype lb (group 2; Fig. 1 
and Table 2), we decided to test a new group of IFN- 
resistant patients (group 2", n=9), predominantly 
infected with genotype lb (Table 2) against a set of 
36 peptides corresponding to the sequence of geno- 
type l b (Table 1). As shown in Fig. 2, a positive 
Fig. 2. IL-2 production against HCV 
E1 synthetic peptides in a group of 
patients who still had high ALT lev- 
els at the end of IFN treatment. The 
sequence of peptides corresponds to 
an isolate of genotype lb. As in Fig. 
1, data are expressed as SI. 
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TABLE 4 
HLA-DR typing of HCV patients 
Group 1 Group 2 Group 3 Group 2* 
Patient HLA- DR Patient HLA-DR Patient HLA-DR Patient HLA-DR 
1 DRB l*0403/DRB4*01011 0 
DRB l*0701/DRB4*01011 
2 DRBI*0103 11 
DRB l * 1102/DRB 3"0202 
3 DRB l*0403/DRB4*01011 2 
4 DRB l*0403/DRB4*01011 3 
5 DRB 1" 1113/DRB3*0202 14 
DRB 1 * 16/DRB5*0102 
6 DRB I*0701/DRB4*01011 5 
DRB 1" 16/DRB5*0101 
7 DRBI*0103 16 
8 DRB l*0403/DRB4*01011 7 
DRB 1 *0407/DRB4*01011 
9 DRBI*0402/DRB4*01011 8 
DRBl*0701/DRB4*01011 
DRB I*0701/DRB4*01011 9 
DRB 1 "0401/DRB4*01011 
DRB 1"03011/DRB3*0201 20 
DRB 1" 16/DRB5*0101 
DRB I*0701/DRB4*01011 21 
DRB 1 * 16/DRB5*0101 
DRBI*1301/DRB3*0101 22 
DRB l*1302/DRB3*0101 
DRB I*0701/DRB4*01011 23 
DRB l*0403/DRB4*01011 
DRB I*0701/DRB4*01011 24 
DRB 1 *0406/DRB4*01011 
DRB 1"0103 25 
DRB l*0701/DRB4*01011 
DRB I*0701/DRB4*01011 26 
DRB 1" 1301/DRB3*0101 
DRBI*0407/DRB4*01011 27 
DRB 1 * 1308/DRB 3"0301 
DRB 1*03011/DRB3*0202 8 ND 
DRBI*0101 
DRBI*0406/DRB4*01011 29 DRB 1*03011/DRB3*0202 
DRB 1 * 1303/DRB3*03033 
DRB l*0406/DRB4*01011 30 ND 
DRBI* 1501/DRB5*0101 31 ND 
DRB 1 * 1104/DRB3*0202 
DRBI*0103 32 ND 
DRB 1 * 1302/DRB 3'0301 
ND 33 ND 
ND 34 DRB 1 *0102 
DRB I*0701/DRB4*01011 
DRB l*0304/DRB3*0202 35 DRBI*0403/DRB4*01011 
DRB l*0406/DRB4*01011 DRB I*0701/DRB4*01011 
ND 36 DRB l*0407/DRB4*01011 
ND: Not determined. 
response was found in only three of them (33%) with 
a mean of 2 peptides per patient being recognized. 
Moreover, only 6 of the 36 (16%) peptides tested 
were recognized in this group of patients. These 
results are comparable to those found in the other 
group of IFN-resistant patients (group 2) tested with 
peptides from the genotype la sequence. 
To exclude general reduction of T lymphocyte 
reactivity in the group of non-responders to IFN, we 
also stimulated PBMC from these patients with a 
mitogen (PHA) and we compared the degree of stim- 
ulation with that obtained in the other groups. As is 
shown in Table 3, the amount of IL-2 produced after 
PHA stimulation was similar in the different groups 
of patients, giving a mean SI of around 130 in all the 
groups. 
To study a possible relationship between the pep- 
tides recognized by the different groups of patients 
and the HLA-DR molecules, determination f HLA- 
DR alleles was performed in most patients with CHC 
(Table 4). We found that the frequency of patients 
with CHC presenting DRBI*04 molecules (50%) 
was significantly higher (p<0.001) than the frequency 
in the normal population (16%, using 219 randomly 
selected Spanish Caucasian individuals, ref. 19). 
Since the design of our experiment is a case-control 
study and not a cohort study, the approximated rela- 
tive risk was estimated using the odds ratio. This 
analysis howed that relative risk of developing CHC 
is approximately 5 times higher in individuals bear- 
ing HLA DRBI*04 (95% confidence limits: 2.2- 
12.7). Peptides 116 and 121 (10 aminoacids over- 
lapped) were recognized by three individuals in 
group 1 (patients #1, 3 and 8). Interestingly, all of 
them have the allele DRB l*0403/DRB4*01011, sug- 
gesting that in some cases the recognition of this lin- 
ear epitope might be associated with this allele. On 
the other hand, DRB I*0701/DRB4*01011 was found 
in eight out of 13 IFN non-responder patients, but 
only in two patients from group 1 (patients #1 and 9). 
Despite the apparent predominance of DRB 1"0701/ 
DRB4*01011 in the group of IFN-resistant patients, 
the difference from the prevalence of this allele in the 
general Spanish population (18%, ref. 19) did not 
reach statistical significance, probably because of the 
small number of cases studied. 
Discussion 
Interferon has, in addition to its direct antiviral prop- 
erties, immunopotentiating activities which are 
thought o contribute to the clearance of viral infec- 
tions (20). In chronic hepatitis C only about 20-30% 
of the patients respond to this treatment (3). In this 
disease the mechanisms responsible for the resistance 
to IFN and the role played by T cell immunity in the 
resolution of HCV infection remain poorly under- 
stood. In the present work we show that most of the 
patients responding to IFN with sustained negativiza- 
tion of viremia demonstrate positive T cell reactivity 
against synthetic peptides from the envelope protein 
E1 while only a minority of IFN resistant patients 
recognized these peptides (p<0.01). In addition, the 
number of peptides inducing IL-2 production in the 
cases exhibiting positive test results was higher 
(p<0.01) among IFN-responders that among IFN- 
resistant patients. Therefore, successful IFN therapy 
appears to be associated with the development of T 
cell response to this viral structural protein. 
These results, concerning T cell response and the 
outcome of IFN treatment, agree with those reported 
by Hoffmann et al. (21) for core protein. These 
authors show that a strong T cell response against 
core protein before and during IFN therapy may be a 
predictor of sustained response. Other authors have 
also reported ata about T cell response against HCV 
antigens, but they have not analyzed this response in 
IFN-responder and IFN-resistant patients. Botarelli et 
al. (7) studied the proliferative T-lymphocyte 
response to different HCV recombinant proteins in 
three groups of subjects: patients with chronic hepati- 
tis C, patients who eliminated the virus after IFN 
treatment and healthy HCV-seropositive individuals. 
These authors found that the percentage of IFN- 
responders who recognized the different structural 
proteins tested (core, E1 and E2) was very low (18%) 
and was similar to that observed in the group of 
patients with chronic hepatitis C. The discrepancy 
between these results and ours (88% of IFN-respon- 
sive patients recognizing peptides from El) might be 
explained by differences in methodology. While the 
authors mentioned used a proliferative assay to test 
the T cell response to viral antigens, we employed a
system based on the production of IL-2 in the pres- 
ence of a monoclonal antibody against the IL-2 
receptor to avoid the consumption of this cytokine. 
This system has been shown to be able to detect IL-2 
production even in cases where the proliferative 
response is absent (22). It is worth noting that despite 
the sensitivity of our assay none of the controls rec- 
ognized any of the peptides tested. The negativity of 
the test for all peptides in these individuals upports 
the specificity of our findings. Saracco et al. (23) 
have reported that anti-E1 antibody levels increased 
in 81.8% of long-term responders to IFN therapy. 
This, in conjunction with our data on the increased T 
cell response to El, suggests that the immune 
response against E1 protein might be associated with 
viral clearance following IFN treatment. 
An intermediate situation between IFN-resistant 
IL-2 production against HCV E1 peptides 
and IFN-responder patients concerning the reactivity 
to E1 peptides is observed in patients with untreated 
chronic hepatitis C with 55% of these cases recogniz- 
ing the peptides from the envelope protein. Interest- 
ingly, in six of these patients who were then treated 
with IFN it was found that the two who failed to rec- 
ognize E1 peptides manifested resistance to the ther- 
apy while three out of four who reacted positively 
against E1 peptides responded favourably to the 
treatment. These preliminary data in conjunction with 
unpublished work from our group (Garcfa-Granero et 
al., manuscript in preparation), demonstrating a high 
rate of T cell response to core peptides in patients 
who responded to IFN therapy and a reduced 
response rate in IFN-resistant cases, further support 
the idea that there is a link between the ability to 
mount a T cell response to viral structural proteins 
and the outcome of IFN treatment. 
Close analysis of individual responses to peptides 
from E1 shows that none of them seem to play the 
role of immunodominant T cell epitope. This might 
be due to the heterogeneity of the HLA-DR mole- 
cules of the patients. Moreover, the role played by 
HLA class II molecules other than HLA-DR cannot 
be ignored. As is well known, these structures are 
responsible for peptide presentation to T cells, thus 
influencing the immunogenicity of a specific peptide 
in each individual. As mentioned, we found that the 
three IFN-responder patients who reacted positively 
against he peptides 116-121 (10 aminoacids over- 
lapped) possessed the allele DRB 1 *0403/ 
DRB4*01011, suggesting that HLA class II mole- 
cules may determine the response against specific lin- 
ear epitopes from HCV. We also observed a signifi- 
cant preponderance of DRBI*04 molecules in the 
total group of patients with CHC. Also we found a 
high, although non-significant proportion of patients 
with the allele DRBI*0701/DRB4*01011 among the 
patients howing IFN resistance. Clearly, the implica- 
tion of HLA-DR molecules in the evolution of HCV 
infection deserves further study. 
One of the perplexing features of this study is the 
absence of T cell responses to E1 antigens in many 
patients with chronic hepatitis C and in most IFN- 
resistant cases, despite continued exposure to viral 
antigens. This lack of response is not due to a general 
immunological depression since T cell function, as 
estimated by the proliferative response to PHA, is 
similar in all groups of patients with CHC and in con- 
trols. Although from our data it cannot be entirely 
excluded that the differences between the sequence of 
the infecting virus and that of the peptide used might 
explain some negative test results, the very low reac- 
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tivity to peptides from E1 in IFN-resistant patients 
appears not be attributable todifferences between the 
virus sequence and the peptides tested. In fact, IFN- 
resistant patients (groups 2 and 2"), mainly infected 
with viral genotype lb, responded almost equally to 
peptides from genotype la and lb. Moreover, com- 
paring the degree of homology between the E1 
sequences used in this paper and other published 
sequences (23 from genotype la and 52 from geno- 
type lb), we found a degree of homology of 94% and 
92% for genotype la and lb, respectively, indicating 
a high degree of conservation of the peptides used in 
this study. 
One of the possible explanations for the low 
response to E1 peptides in groups 2, 2* and 3 is that 
E1 might not be a strong immunogen. In fact, in 
patients with chronic hepatitis C a higher stimulatory 
index was obtained when using core peptides than 
when using E1 peptides in the assay system (Garcfa- 
Granero et al. unpublished observations). Similarly, 
Ferrari et al. (9) have shown that chronic hepatitis C
patients respond more intensely to recombinant core 
protein than to recombinant El. Nevertheless, with 
the sensitive IL-2 production assay used in the 
present work we were able to detect positive 
responses to E1 in almost all the patients who cleared 
the virus after IFN therapy, suggesting that E1 deter- 
minants are capable of inducing cellular immunity. 
Therefore, hypotheses other than the low immuno- 
genicity of E1 should be considered to explain the 
lack of responses to this immunogen observed in 
patients with chronic HCV infection. Further studies 
are needed to evaluate whether HCV infection might 
cause deletion of specific reactive T cell clones or 
whether HCV can evade immunoclearance through 
the induction of immunosuppressive cytokines. In 
this respect it has been recently shown (24) that the 
expression of TGF-[3 1, a strong immunosuppressor, 
is markedly increased in the liver of patients with 
chronic hepatitis C. 
Another point deserving comment is the finding of 
T cell reactivity against E1 in half the cases with 
untreated chronic hepatitis C and in some chronic 
hepatitis C patients with continued isease activity 
after IFN treatment. These findings indicate that 
HCV can avoid immunoclearance d spite T helper 
cell recognition. The mechanisms of this escape from 
the immune system are not well understood. As in 
other viral infections, cytotoxic T cells are thought to 
be the main effectors in the control of viral infection 
and in the elimination of virus-infected cells. It is 
conceivable that modulation of the cytokine network 
by HCV might result in inhibition of the cytotoxic T
cell response ven in the presence of appropriate T 
helper cell reactivity. Studies are at present underway 
in our laboratory to analyze the cytotoxic T cell 
response in similar groups of patients to those studied 
in the present paper. 
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